European Pharmaceutical Review

MARCH 11, 2024

In a review on fungal-contaminated compounded pharmaceuticals and medical devices, researchers have described how the contamination of these products can be due to breaches in sterile compounding procedures. Ahmed et al. Ahmed et al. One case of drug contamination from 2021 was highlighted in the paper.

Sterile Compounds 82

Sterile Compounds Compounding Packaging Pharmaceutical Companies 82

Pharmaceutical Technology

DECEMBER 9, 2022

Research and development highlights from the research period include the company’s work with Mirati Therapeutics in developing methods to determine torsion rotational energy barriers of the clinical compound, MRTX1719, which is being developed for use as an inhibiter to MTAP-deleted cancers. Assays to support mRNA-based Covid-19 vaccines.

Vaccines 52

Vaccines Compounding FDA Packaging 52

pharmaphorum

SEPTEMBER 21, 2021

“The future manufacturing of APIs for our medicines includes compounds with highly complex synthesis, requiring next generation technologies and capabilities that can respond quickly and nimbly to rapidly-changing clinical and commercial needs,” said Pam Cheng, AZ’s executive vice president of global operations and IT.

Packaging 59

Packaging Compounding Vaccines FDA 59

ISPE

MARCH 8, 2023

Identification and Analysis of Contamination Trends Three major recall databases—those of the US FDA, the United Kingdom’s Medicine and Healthcare Products Regulatory Agency (UK MHRA), and Australia’s Therapeutic Goods Administration (TGA)—were searched to assess contamination trends in the past five years.

Compounding 52

Compounding Compounding Pharmacies Packaging FDA 52

pharmaphorum

MAY 26, 2022

The race to produce a vaccine which could protect the world against COVID-19 brought the topic of diversity in clinical trials, or lack of it, into sharp focus. Vaccines approved for public use require comprehensive RCTs to establish their safety and efficacy. The pandemic brought imbalances into sharp focus. About the authors.

Packaging 143

Packaging Vaccines Generic Medicine Compounding 143

ISPE

SEPTEMBER 11, 2023

4 , 5 Additionally, reducing shipping limitations—such as packaging, storage, and transportation durations—helps speed up patient access in certain instances while ensuring there is no negative impact to the product’s critical quality attributes (CQAs). These new operating models can help enable and accelerate the efforts of Pharma 4.0™

Health and Personal Care Stores 52

Health and Personal Care Stores Vaccines Packaging Documentation 52

ISPE

AUGUST 30, 2022

With shortages, regulatory complexity is compounded due to differences in submission and data requirements from various regulatory agencies. In this article, the term “raw material” refers to a material used in the manufacturing and packaging of a drug substance (DS) or a drug product (DP). Burke, PhD. 1 September 2022.

Documentation 52

Documentation FDA Packaging Communication 52